Ioflubenzamide I-131
Alternative Names: 131-I-MIP-1145; BA-100; Iodine-123 ZK-BA; Iodine-131 ZK-BA; MIP-1145; Solazed; ZK BALatest Information Update: 23 Jan 2013
Price :
$50 *
At a glance
- Originator Bayer Schering Pharma
- Developer Molecular Insight Pharmaceuticals
- Class Antineoplastics; Benzamides; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Malignant melanoma
Most Recent Events
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
- 07 Oct 2011 Molecular Insight Pharmaceuticals terminates a phase I trial in Malignant melanoma in USA (NCT00747825)
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals